Heparin/collagen surface coatings modulate the growth, secretome, and morphology of human mesenchymal stromal cell response to interferon-gamma
Said J. Cifuentes
Bioengineering Graduate Program, University of Puerto Rico Mayaguez, Mayaguez, Puerto Rico, USA
Search for more papers by this authorPriyanka Priyadarshani
Regenerative Bioscience Center, Rhodes Center for ADS, University of Georgia, Athens, Georgia, USA
School of Chemical, Materials and Biomedical Engineering, University of Georgia, Athens, Georgia, USA
Search for more papers by this authorDavid A. Castilla-Casadiego
Ralph E. Martin Department of Chemical Engineering, University of Arkansas, Fayetteville, Arkansas, USA
Search for more papers by this authorLuke J. Mortensen
Regenerative Bioscience Center, Rhodes Center for ADS, University of Georgia, Athens, Georgia, USA
School of Chemical, Materials and Biomedical Engineering, University of Georgia, Athens, Georgia, USA
Search for more papers by this authorCorresponding Author
Jorge Almodóvar
Ralph E. Martin Department of Chemical Engineering, University of Arkansas, Fayetteville, Arkansas, USA
Correspondence
Jorge Almodóvar, Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, AR 72701, USA.
Email: [email protected]
Maribella Domenech, Bioengineering Graduate Program, University of Puerto Rico Mayaguez Call Box 9000, Mayaguez, PR 00681-9000, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Maribella Domenech
Bioengineering Graduate Program, University of Puerto Rico Mayaguez, Mayaguez, Puerto Rico, USA
Department of Chemical Engineering, University of Puerto Rico Mayagüez, Mayagüez, Puerto Rico, USA
Correspondence
Jorge Almodóvar, Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, AR 72701, USA.
Email: [email protected]
Maribella Domenech, Bioengineering Graduate Program, University of Puerto Rico Mayaguez Call Box 9000, Mayaguez, PR 00681-9000, USA.
Email: [email protected]
Search for more papers by this authorSaid J. Cifuentes
Bioengineering Graduate Program, University of Puerto Rico Mayaguez, Mayaguez, Puerto Rico, USA
Search for more papers by this authorPriyanka Priyadarshani
Regenerative Bioscience Center, Rhodes Center for ADS, University of Georgia, Athens, Georgia, USA
School of Chemical, Materials and Biomedical Engineering, University of Georgia, Athens, Georgia, USA
Search for more papers by this authorDavid A. Castilla-Casadiego
Ralph E. Martin Department of Chemical Engineering, University of Arkansas, Fayetteville, Arkansas, USA
Search for more papers by this authorLuke J. Mortensen
Regenerative Bioscience Center, Rhodes Center for ADS, University of Georgia, Athens, Georgia, USA
School of Chemical, Materials and Biomedical Engineering, University of Georgia, Athens, Georgia, USA
Search for more papers by this authorCorresponding Author
Jorge Almodóvar
Ralph E. Martin Department of Chemical Engineering, University of Arkansas, Fayetteville, Arkansas, USA
Correspondence
Jorge Almodóvar, Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, AR 72701, USA.
Email: [email protected]
Maribella Domenech, Bioengineering Graduate Program, University of Puerto Rico Mayaguez Call Box 9000, Mayaguez, PR 00681-9000, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Maribella Domenech
Bioengineering Graduate Program, University of Puerto Rico Mayaguez, Mayaguez, Puerto Rico, USA
Department of Chemical Engineering, University of Puerto Rico Mayagüez, Mayagüez, Puerto Rico, USA
Correspondence
Jorge Almodóvar, Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, AR 72701, USA.
Email: [email protected]
Maribella Domenech, Bioengineering Graduate Program, University of Puerto Rico Mayaguez Call Box 9000, Mayaguez, PR 00681-9000, USA.
Email: [email protected]
Search for more papers by this authorFunding information: Center for the Advancement of Wearable Technologies, National Science Foundation, Grant/Award Number: OIA-1849243; Engineering Center for Cell Manufacturing Technologies, National Science Foundation, Grant/Award Number: EEC-1648035; PUERTO RICO IDEA NETWORK OF BIOMEDICAL RESEARCH EXCELLENCE, National Institute of Health, Grant/Award Number: P20 GM103475-15
Abstract
The therapeutic potential of human mesenchymal stromal cells (h-MSC) is dependent on the viability and secretory capacity of cells both modulated by the culture environment. Our previous studies introduced heparin and collagen I (HEP/COL) alternating stacked layers as a potential substrate to enhance the secretion of immunosuppressive factors of h-MSCs. Herein, we examined the impact of HEP/COL multilayers on the growth, morphology, and secretome of bone marrow and adipose-derived h-MSCs. The physicochemical properties and stability of the HEP/COL coatings were confirmed at 0 and 30 days. Cell growth was examined using cell culture media supplemented with 2 and 10% serum for 5 days. Results showed that HEP/COL multilayers supported h-MSC growth in 2% serum at levels equivalent to 10% serum. COL and HEP as single component coatings had limited impact on cell growth. Senescent studies performed over three sequential passages showed that HEP/COL multilayers did not impair the replicative capacity of h-MSCs. Examination of 27 cytokines showed significant enhancements in eight factors, including intracellular indoleamine 2, 3-dioxygenase, on HEP/COL multilayers when stimulated with interferon-gamma (IFN-γ). Image-based analysis of cell micrographs showed that serum influences h-MSC morphology; however, HEP-ended multilayers generated distinct morphological changes in response to IFN-γ, suggesting an optical detectable assessment of h-MSCs immunosuppressive potency. This study supports HEP/COL multilayers as a culture substrate for undifferentiated h-MSCs cultured in reduced serum conditions.
CONFLICT OF INTEREST
The authors declare no potential conflict of interest.
Supporting Information
| Filename | Description |
|---|---|
| jbma37085-sup-0001-supinfo.docxWord 2007 document , 209 KB | Appendix S1: Supporting information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Zou J-P, Huang S, Peng Y, et al. Mesenchymal stem cells/multipotent mesenchymal stromal cells (MSCs). Int J Low Extrem Wounds. 2012; 11: 244-253.
- 2Castilla-Casadiego DA, Reyes-Ramos AM, Domenech M, Almodovar J. Effects of physical, chemical, and biological stimulus on h-MSC expansion and their functional characteristics. Ann Biomed Eng. 2019; 47: 1-17.
- 3Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014; 14: 141-145.
- 4Meirelles L d S, da Silva Meirelles L. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006; 119: 2204-2213.
- 5Dulamea A. Mesenchymal stem cells in multiple sclerosis - translation to clinical trials. Med Life. 2015; 8: 24-27.
- 6Bosi CA, Lanzoni G, Pugliese A. Clinical trials of mesenchymal stem cell transplantation in patients with type 1 diabetes and systemic lupus erythematosus: is it time for larger studies? CellR4. 2016; 4(5):e2134.
- 7Lipsitz YY, Milligan W, Fitzpatrick I, et al. A roadmap for cost-of-goods planning to guide economic production of cell therapy products. Cytotherapy. 2017; 19: 1383-1391.
- 8Simaria AS, Hassan S, Varadaraju H, et al. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol Bioeng. 2014; 111: 69-83.
- 9Kim HJ, Park J-S. Usage of human mesenchymal stem cells in cell-based therapy: advantages and disadvantages. Dev Reprod. 2017; 21: 1-10.
- 10Jenkins MJ, Farid SS. Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies. Biotechnol J. 2015; 10: 83-95.
- 11Want AJ, Nienow AW, Hewitt CJ, Coopman K. Large-scale expansion and exploitation of pluripotent stem cells for regenerative medicine purposes: beyond the T flask. Regen Med. 2012; 7: 71-84.
- 12Hanley PJ, Mei Z, Cabrera-Hansen MG, et al. Manufacturing mesenchymal stromal cells for phase I clinical trials. Cytotherapy. 2013; 15: 416-422.
- 13Gottipamula S, Muttigi MS, Kolkundkar U, Seetharam RN. Serum-free media for the production of human mesenchymal stromal cells: a review. Cell Prolif. 2013; 46: 608-627.
- 14Ng F, Boucher S, Koh S, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood. 2008; 112: 295-307.
- 15Agata H, Watanabe N, Ishii Y, et al. Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Biochem Biophys Res Commun. 2009; 382: 353-358.
- 16Rodrigues CAV, Fernandes TG, Diogo MM, da Silva CL, Cabral JMS. Stem cell cultivation in bioreactors. Biotechnol Adv. 2011; 29: 815-829.
- 17Girdlestone J, Pido-Lopez J, Srivastava S, et al. Enhancement of the immunoregulatory potency of mesenchymal stromal cells by treatment with immunosuppressive drugs. Cytotherapy. 2015; 17: 1188-1199.
- 18Samsonraj RM, Rai B, Sathiyanathan P, et al. Establishing criteria for human mesenchymal stem cell potency. Stem Cells. 2015; 33(6): 1878-1891.
- 19Kuraitis D, Giordano C, Ruel M, Musarò A, Suuronen EJ. Exploiting extracellular matrix-stem cell interactions: a review of natural materials for therapeutic muscle regeneration. Biomaterials. 2012; 33: 428-443.
- 20Yeo GC, Weiss AS. Soluble matrix protein is a potent modulator of mesenchymal stem cell performance. Proc Natl Acad Sci U S A. 2019; 116(6): 2042-2051.
- 21Saei-Arezoumand K, Alizadeh E, Pilehvar-Soltanahmadi Y, Esmaeillou M, Zarghami N. An overview on different strategies for the stemness maintenance of MSCs. Artif Cells Nanomed Biotechnol. 2017; 45: 1255-1271.
- 22Lee JH, Luo X, Ren C, et al. A Heparan sulfate device for the regeneration of osteochondral defects. Tissue Eng Part A. 2019; 25: 352-363.
- 23Monge C, Almodóvar J, Boudou T, Picart C. Spatio-temporal control of LbL films for biomedical applications: from 2D to 3D. Adv Healthc Mater. 2015; 4: 811-830.
- 24Boudou T, Crouzier T, Ren K, Blin G, Picart C. Multiple functionalities of polyelectrolyte multilayer films: new biomedical applications. Adv Mater. 2010; 22(4): 441-467.
- 25Picart C, Mutterer J, Arntz Y, Voegel JC, Schaaf P, Senger B. Application of fluorescence recovery after photobleaching to diffusion of a polyelectrolyte in a multilayer film. Microsc Res Tech. 2005; 66(1): 43-57.
- 26Mhanna RF, Vörös J, Zenobi-Wong M. Layer-by-layer films made from extracellular matrix macromolecules on silicone substrates. Biomacromolecules. 2011; 12(3): 609-616.
- 27Muzzio NE, Pasquale MA, Gregurec D, et al. Polyelectrolytes multilayers to modulate cell adhesion: a study of the influence of film composition and polyelectrolyte Interdigitation on the adhesion of the A549 cell line. Macromol Biosci. 2016; 16: 482-495.
- 28Fichtner M, Claus C, Lessig-Owlanj J, Arnhold J, Reibetanz U. The application of LbL-microcarriers for the treatment of chronic inflammation: monitoring the impact of LbL-microcarriers on cell viability. Macromol Biosci. 2015; 15: 546-557.
- 29Castilla-Casadiego DA, García JR, García AJ, Almodovar J. Heparin/collagen coatings improve human mesenchymal stromal cell response to interferon gamma. ACS Biomater Sci Eng. 2019; 5: 2793-2803.
- 30Castilla-Casadiego DA, Pinzon-Herrera L, Perez-Perez M, Quiñonez-Colon B, Suleiman D, Almodovar J. Simultaneous characterization of physical, chemical, and thermal properties of polymeric multilayers using infrared spectroscopic ellipsometry. Colloids Surf A. 2018; 553: 155-168.
- 31Haasters F, Prall WC, Anz C, et al. Morphological and immunocytochemical characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing. J Anat. 2009; 214: 759-767.
- 32Decher G, Hong JD, Schmitt J. Buildup of ultrathin multilayer films by a self-assembly process: III. Consecutively alternating adsorption of anionic and cationic polyelectrolytes on charged surfaces. Thin Solid Films. 1992; 210-211: 831-835.
- 33Jha AK, Mathur A, Svedlund FL, Ye J, Yeghiazarians Y, Healy KE. Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate. J Control Release. 2015; 209: 308-316.
- 34Martino MM, Briquez PS, Ranga A, Lutolf MP, Hubbell JA. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A. 2013; 110: 4563-4568.
- 35Sasisekharan R. Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol. 2000; 4: 626-631.
- 36Brindley DA, Davie NL, Culme-Seymour EJ, Manson C, Smith DW, Rowley JA. Peak serum: implications of serum supply for cell therapy manufacturing. Regen Med. 2012; 7: 7-13.
- 37Xuegang Y, Logan T, Ma T. Metabolism in human mesenchymal stromal cells: a missing link between hMSC biomanufacturing and therapy? Front Immunol. 2019; 10: 977.
- 38Wang G, Kao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ. 2018; 25: 1209-1223.
- 39Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014; 6: 526-539.
- 40Cesarz Z, Tamama K. Spheroid culture of mesenchymal stem cells. Stem Cells Int. 2016; 2016: 1-11.
- 41Burkin DJ, Jones C, Kimbro KS, Taylor MW, Barr BL, Gupta SL. Localization of the human indoleamine 2,3-dioxygenase (IDO) gene to the pericentromeric region of human chromosome 8. Genomics. 1993; 17: 262-263.
- 42Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005; 109: 227-241.
- 43Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Gene Dev. 2008; 22: 1276-1312.
- 44Wu J, Huang GT, He W, et al. Basic fibroblast growth factor enhances stemness of human stem cells from the apical papilla. J Endod. 2012; 38: 614-622.
- 45Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci. 2012; 122: 143-159.
- 46Scheller J, Chalaris A. Schmidt-Arras; D.; rose-John, S. the pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 1813; 2011: 878-888.
- 47Jacques C, Gosset M, Berenbaum F, Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm. 2006; 74: 371-403.
- 48Choi P, Reiser H. IL-4: role in disease and regulation of production. Clin Exp Immunol. 1998; 113: 317-319.
- 49Beutler B, Cerami A. The biology of cachectin/TNF–a primary mediator of the host response. Annu Rev Immunol. 1989; 7: 625-655.
- 50Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. Onco Targets Ther. 2013; 2(7):e25443.
- 51Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med. 2013; 2(6): 455-463.
- 52Klinker MW, Marklein RA, Lo Surdo JL, Wei C-H, Bauer SR. Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity. Proc Natl Acad Sci U S A. 2017; 114: E2598-E2607.
- 53Marklein RA, Klinker MW, Drake KA, Polikowsky HG, Lessey-Morillon EC, Bauer SR. Morphological profiling using machine learning reveals emergent subpopulations of interferon-γ-stimulated mesenchymal stromal cells that predict immunosuppression. Cytotherapy. 2019; 21: 17-31.
- 54Schwartz MA, Assoian RK. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci. 2001; 114(14): 2553-2560.
- 55Tsai CC, Chen YJ, Yew TL, et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood Am J Hematol. 2011; 117(2): 459-469.
- 56Tang H, Xiang Y, Jiang X, et al. Dual expression of hTERT and VEGF prolongs life span and enhances angiogenic ability of aged BMSCs. Biochem Biophys Res Commun. 2013; 440(4): 502-508.
- 57Ueyama H, Horibe T, Hinotsu S, et al. Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions. J Cell Mol Med. 2012; 16(1): 72-82.
- 58Gronthos S, Chen S, Wang CY, Robey PG, Shi S. Telomerase accelerates osteogenesis of bone marrow stromal stem cells by upregulation of CBFA1, osterix, and osteocalcin. J Bone Miner Res. 2003; 18(4): 716-722.
- 59Pourgholaminejad A, Aghdami N, Baharvand H, Moazzeni SM. The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells. Cytokine. 2016; 85: 51-60.
- 60Kim DS, Jang IK, Lee MW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ. EBioMedicine. 2018; 28: 261-273.
- 61Arumuggam N, Bhowmick NA, Rupasinghe HP. A review: phytochemicals targeting JAK/STAT signaling and IDO expression in cancer. Phytother Res. 2015; 29: 805-817.
- 62Riopel M, Wang R. Collagen matrix support of pancreatic islet survival and function. Front Biosci. 2014; 19: 77-90.
- 63Hind HG, Mcginn SM. Heparin content of adipose tissue. Nature. 1958; 182: 117-117.
- 64Butterfield JH, Li C-Y. Bone marrow biopsies for the diagnosis of systemic Mastocytosis: is one biopsy sufficient? Am J Clin Pathol. 2004; 121: 264-267.
- 65Martin C, Olmos E, Collignon ML, et al. Revisiting MSC expansion from critical quality attributes to critical culture process parameters. Process Biochem. 2017; 59: 231-243.
- 66Avila MI, Rodriguez LG, Sánchez ML. Collagen: a review on its sources and potential cosmetic applications. J Cosmet Dermatol. 2018; 17(1): 20-26.
- 67Onishi A, St Ange K, Dordick JS, Linhardt RJ. Heparin and anticoagulation. Front Biosci. 2016; 21: 1372-1392.
- 68 US Food and Drug Administration. Guidance for FDA reviewers and sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs). Center for Biologics Evaluation and Research. 2008
Citing Literature
